OTS - ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS (part 2)
2022. September 08. 09:23
Lausanne, Switzerland, 8 September, 2022 (APA/OTS) -
About afabicin
Afabicin (Debio 1450) is Debiopharm's first-in-class FabI
inhibitor against Staphylococcus spp., whose sub-class
Methicillin-resistant Staphylococcus aureus (MRSA) is high on the
WHO global priority pathogen list and deemed a "serious threat" by
the CDC. Afabicin can be administered orally or IV and selectively
targets Staphylococcus' essential bacterial fatty acid
biosynthesis. Promising results have been obtained in a comparative
double-blind Phase 2 trial with afabicin in acute bacterial skin
and skin structure infections. Currently, an international Phase 2
trial in bone and joint infections is being conducted comparing
afabicin to standard antibiotics.
About Debio 1453 and Debio 1454S
Analogous to Afabicin, the preclinical compounds Debio 1453 and
Debio 1454S are potential first in class pathogen-specific drugs
targeting the essential bacterial fatty acid biosynthesis. Debio
1453 can be administered orally or intramuscularly to treat
Neisseria gonorrhoeae infections while Debio 1454S is being
developed for IV use in cases of hospital-acquired pneumonia and
ventilator-associated pneumonia caused by carbapenem-resistant
Acinetobacter baumannii.
Debiopharm's fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical
company is one of the few privately owned companies developing
novel class antibiotics to combat hard-to-treat infections. Through
their unique partnership-based business model, the company is
advancing pathogen-specific antibiotics from early stage through
phase II clinical research with afabicin, specifically targeting
staphylococci, being the most clinically advanced for the treatment
of bone and joint infections. As a result of high selectivity, FabI
inhibitors specifically target selected pathogens while preserving
intestinal microbiota and meet all four WHO 2020 innovation
criteria: new chemical class, new target, new mode of action and no
cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton
Communication Manager
dawn.haughton@debiopharm.com
Tel: +41 (0)21 321 01 11
References
[1] Antimicrobial Resistance Collaborators. Global burden of
bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022;399(10325):629-655.
[2] CDC Antibiotic resistance threats in the United States,
2019.
https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
[3] Cassini A, et al. Attributable deaths and
disability-adjusted life-years caused by infections with
antibiotic-resistant bacteria in the EU and the European Economic
Area in 2015: a population-level modelling analysis. Lancet Infect
Dis. 2019;19(1):56-66.
[4] CDC Antibiotic resistance threats in the United States,
2013. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.